The Federal Commission for Protection against Health Risks (Cofepris) has authorized the creation of the Mexican Association of Medical Cannabis, confirmed Dr. Gady Zabicky.
Zabicky, a psychiatrist and addiction specialist, announced the professional group’s creation at the press conference for the Weed Expo in Mexico City. The purpose of the association will be to investigate the potential of marijuana and its components cannabinoids for the medical treatment of various diseases.
Zabicky is one of the organizers of the Weed Expo México, which will be held from August 18 to 20, a meeting in which will be a Consultancy in Cannabis Medicine to all patients interested in knowing if the diseases that afflict them can receive treatments with medicinal substances of cannabinoide content (CBG).
It should be noted that during the Expo Weed neither medicines nor treatments will be provided, as the consultancy aims to guide patients and in case of proceeding with any treatment, the patient must comply with the requirements requested by Cofepris to acquire this type of medication.
In announcing the creation of the Mexican Association of Medical Cannabis, Dr. Gady Zabicky said that Cofepris’s permission is the result of years of work by activists, doctors, patients, and people interested in achieving treatment for diseases that can be treated with the cannabinoids.
For his part, Dr. Alfonso Martín del Campo, a psychopharmacologist and psychiatrist, said that the authorization is a historic opportunity in Mexico to make progress in the treatment of many diseases and finally legalize the use of marijuana for medicinal purposes in the country.
He also remarked that it has opened the possibility of resuming the ancestral medical use of this plant in Mexico, in addition to emphasizing that marijuana has many other commercial and industrial applications.
Scientists have recently developed advanced protocols harnessing the power of exosomes to create a new class of therapeutics to improve the effectiveness of stem cell therapy. In particular, they have developed new protocols for neurological diseases such as Alzheimer´s, Parkinson´s, Autism and Multiple Sclerosis. Read More